| Literature DB >> 12437781 |
John B Mailhes1, Colette Hilliard, Mary Lowery, Steve N London.
Abstract
BACKGROUND: Although chromosome missegregation during oocyte maturation (OM) is a significant contributor to human morbidity and mortality, very little is known about the causes and mechanisms of aneuploidy. Several investigators have proposed that temporal perturbations during OM predispose oocytes to aberrant chromosome segregation. One approach for testing this proposal is to temporarily inhibit the activity of protein proteolysis during OM. We used the reversible proteasome inhibitor MG-132 to transiently perturb the temporal sequence of events during OM and subsequently analyzed mouse metaphase II (MII) for cytogenetic abnormalities. The transient inhibition of proteasome activity by MG-132 resulted in elevated levels of oocytes containing extra chromatids and chromosomes.Entities:
Year: 2002 PMID: 12437781 PMCID: PMC149371 DOI: 10.1186/1475-9268-1-2
Source DB: PubMed Journal: Cell Chromosome ISSN: 1475-9268
Figure 1Cytogenetic analysis of mouse oocytes following in vitro exposure to MG-132, chromosome configurations are shown. (A) metaphase II oocyte, normal, n = 20 dyads. (B) metaphase I oocyte, normal, N = 20 tetrads. (C) metaphase II oocyte, hypoploid, premature centromere separation (incomplete), n = 19 1/2 (10 dyads and 19 chromatids), arrow points to one of the 19 single, unpaired chromatids. (D) metaphase II oocyte, hyperploid, n= 22 dyads. (E) metaphase II oocyte, hyperploid, single-unpaired chromatid, n = 20 1/2 (20 dyads and one single, unpaired chromatid indicated by arrow). (F) metaphase I oocyte, diffuse chromatin, N= 20 probable tetrads. (G) metaphase I oocyte, homologue separation, N= 20 (17 tetrads and 6 dyads), arrow points to one of the 6 dyads. (H) metaphase I oocyte, homologue separation, N= 19 1/2 (16 tetrads and 7 dyads).
Cytogenetic analysis of mouse metaphase II oocytes following in vitro exposure to the proteasome inhibitor MG-132
| MG-132 (mcg/ml) | No. cells analyzed | No. MI oocytes (%) | No. MII oocytes (%) | No. premature centromere separation (%) | No. single chromatids (%) | No. haploid (%) | No. hypoploid (%) | No. hyperploid (%) |
| Control | 130 | 13 (10.0)a | 117 (90.0) | 43 (36.8)a | 1 (0.9)a | 101 (86.3) | 16 (13.7) | -0-a |
| 5.0 | 158 | 19 (12.0)a | 139 (88.0) | 38 (27.3) | 3 (2.2)a,b | 121 (87.1) | 18 (12.9) | -0-a |
| 7.5 | 191 | 26 (13.6)a | 165 (86.4) | 44 (26.7) | 11 (6.7)b | 142 (86.1) | 18 (10.9) | 5 (3.0)b |
| 10.0 | 125 | 53 (42.4)b | 72 (57.6) | 13 (18.1)b | 11 (15.3)c | 62 (86.1) | 3 (4.2) | 7 (9.7)c |
Different superscripts among proportions in the same column indicate significant (P < 0.01) differences.